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Nutlin-3a selects for cells harbouring TP53 mutations
Jill E. Kucab1, Monica Hollstein2,3, Volker M. Arlt1 and David H. Phillips1
1 King’s College London, Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment & Health, London, United Kingdom
2 German Cancer Research Center (Deutsches Krebsforschungszentrum), Division of Genetic Alterations in Carcinogenesis, Heidelberg, Germany
3 University of Leeds, Faculty of Medicine and Health, Leeds, United Kingdom
TP53mutations occur in half of all human tumours. Mutagen-induced or spontaneous TP53mutagenesis can be studied in vitro
using the human TP53 knock-in (Hupki) mouse embryo fibroblast (HUF) immortalisation assay (HIMA). TP53mutations arise in up
to 30% of mutagen-treated, immortalised HUFs; however, mutants are not identified until TP53 sequence analysis following
immortalisation (2–5 months) and much effort is expended maintaining TP53-WT cultures. In order to improve the selectivity of
the HIMA for HUFs harbouring TP53mutations, we explored the use of Nutlin-3a, an MDM2 inhibitor that leads to stabilisation and
activation of wild-type (WT) p53. First, we treated previously established immortal HUF lines carrying WT or mutated TP53 with
Nutlin-3a to examine the effect on cell growth and p53 activation. Nutlin-3a induced the p53 pathway in TP53-WT HUFs and
inhibited cell growth, whereas most TP53-mutated HUFs were resistant to Nutlin-3a. We then assessed whether Nutlin-3a treat-
ment could discriminate between TP53-WT and TP53-mutated cells during the HIMA (n572 cultures). As immortal clones emerged
from senescent cultures, each was treated with 10 mM Nutlin-3a for 5 days and observed for sensitivity or resistance. TP53 was
subsequently sequenced from all immortalised clones. We found that all Nutlin-3a-resistant clones harboured TP53mutations,
which were diverse in position and functional impact, while all but one of the Nutlin-3a-sensitive clones were TP53-WT. These data
suggest that including a Nutlin-3a counter-screen significantly improves the specificity and efficiency of the HIMA, whereby
TP53-mutated clones are selected prior to sequencing and TP53-WT clones can be discarded.
The transcription factor p53 plays a vital role in the cellular
response to stresses such as DNA damage. Depending on the
severity of the stress, p53 can direct a cell toward cell cycle
arrest, DNA repair or apoptosis by regulating the transcription
of an array of genes.1 By preventing the growth of stressed or
damaged cells, p53 acts as a key tumour suppressor. The gene
encoding p53, TP53, is mutated in over half of all cancers.2 The
majority of TP53 mutations in cancer are missense and occur
in the DNA-binding domain coding region (exons 5–8). Typi-
cally, TP53-mutated cells accumulate excessive levels of mutant
protein that is unable to transcriptionally transactivate canoni-
cal p53 target genes and may possess new, gain-of-function
activities.3 A comprehensive study of the transactivational
capability of p53 mutants, representing all possible amino acid
substitutions caused by point mutation, demonstrated that
human tumour-associated mutations are strongly correlated
with inactivation of p53 function.4
Analysis of TP53 mutations detected in human tumours,
which are diverse in type, position and functional impact, has
established correlations between speciﬁc mutation signatures
and exposure to certain environmental mutagens (e.g. C>T and
CC>TT mutations in head and neck squamous carcinomas,
associated with ultraviolet (UV)-radiation exposure; G>T
mutations in smokers’ lung cancers, associated with exposure to
tobacco carcinogens, such as benzo[a]pyrene (BaP); A>T
mutations in urothelial carcinomas, associated with exposure to
aristolochic acid (AA).2 Some of these signatures have been
replicated experimentally using embryo ﬁbroblasts from the
partial human TP53 knock-in (Hupki) mouse, in which exons
4–9 of human TP53 replace the corresponding exons of murine
Trp53.5–7
The Hupki mouse embryo ﬁbroblast (HUF) immortalisa-
tion assay (or HIMA) was designed to generate and select for
TP53 mutations in a mammalian cell context, taking advan-
tage of the fact that mutation or loss of TP53 is a key
Key words: TP53, mutation, Nutlin-3a, Hupki, immortalisation
Abbreviations: AA: aristolochic acid; BaP: benzo[a]pyrene; HIMA:
HUF immortalisation assay; HUF: Hupki mouse embryo
fibroblast; Hupki: human TP53 knock-in; MEF: mouse embryo
fibroblast; UV: ultraviolet
Additional Supporting Information may be found in the online
version of this article.
Volker M. Arlt1 and David H. Phillips are joint senior authors.
Grant sponsor: Cancer Research UK; Grant number: C313/A14329;
Grant sponsor: Wellcome Trust; Grant numbers: 101126/B/13/Z
and 101126/Z/13/Z
DOI: 10.1002/ijc.30504
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
History: Received 6 July 2016; Accepted 14 Oct 2016; Online 4 Nov
2016
Correspondence to: Jill E. Kucab, Analytical and Environmental
Sciences Division, MRC-PHE Centre for Environment & Health,
King’s College London, Franklin-Wilkins Building, 150 Stamford
Street, London SE1 9NH, United Kingdom, Tel.: 144-207-848-3781,
E-mail: jill.kucab@kcl.ac.uk
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
Int. J. Cancer: 140, 877–887 (2017) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
International Journal of Cancer
IJC
mechanism enabling the immortalisation of HUFs. Mutations
may be carcinogen-induced or arise spontaneously and can be
compared to the TP53 mutation spectra found in human
tumours to explore potential links with cancer aetiology. For
the HIMA, cultures of primary HUFs are ﬁrst treated with a
carcinogen of interest. Treated HUFs, along with untreated con-
trol cultures, are then serially passaged according to a modiﬁed
3T3 protocol.8,9 The majority of HUFs will undergo p53-
dependent senescent growth arrest, due to the sensitivity of
mouse cells to atmospheric oxygen levels in standard cell cul-
ture (20%). HUFs that have accumulated mutations (e.g. in
TP53) that permit senescence bypass will continue to proliferate
as clonal populations and ultimately become established into
immortalised cell lines. This selection process takes between 2
and 5 months, as some immortal clones emerge relatively
quickly from senescent cultures, whereas other clones take lon-
ger to develop. DNA from the immortalised HUFs is then
sequenced to identify TP53 mutations. Previous studies have
detected TP53 mutations in up to 30% of mutagen-treated cul-
tures or 5 to 20% of spontaneously immortalised cultures.10–13
The remaining cultures are TP53-WT and likely harbour altera-
tions in other genes associated with senescence-bypass.14,15
Because the HIMA mutant selection process (i.e. senescence
bypass) is not fully speciﬁc for TP53-mutated cells, the majority
of the effort of the assay is expended maintaining TP53-wild-
type (WT) cultures. An additional selection procedure to dis-
tinguish between cells harbouring WT or mutated TP53 would
greatly improve the efﬁciency of the assay. Such a selection step
would ideally inhibit growth of HUFs containing WT TP53
while permitting growth of TP53-mutated cells. Pharmacologi-
cal activation of p53 to arrest or kill tumour cells retaining
WT TP53 is currently an active ﬁeld of research in cancer ther-
apeutics.16 One emergent strategy is to disrupt the binding of
p53 to its negative regulator MDM2. MDM2 inhibits p53 by:
(i) ubiquitinating p53 to promote its proteasomal degrada-
tion;17 (ii) binding to the N-terminal activation domain of p53,
masking its ability to activate transcription;18 and (iii) partici-
pating in the nuclear export of p53.19 In turn, p53 regulates
MDM2 expression at the level of transcription as part of an
autoregulatory feedback loop.20
Nutlin-3a, a cis-imidazoline analogue, binds the p53-binding
pocket of MDM2, inhibiting the interaction of MDM2 and p53
and resulting in p53 stabilisation and activation.21 Nutlin-3a is
non-genotoxic, thus endogenous cellular stress may initiate
activation of stabilised p53.22 Treatment of cells with Nutlin-3a
can induce the expression of p53 target genes (e.g. p21WAF1/Cip1
and MDM2) and has been shown to induce arrest or apoptosis
of cancer cells expressing WT p53.23,24 Crucially, Nutlin-3a spe-
ciﬁcally induced senescence of mouse embryo ﬁbroblasts (MEFs)
with WT Trp53 but did not affect the growth of Trp53-null
MEFs.22 MEFs deﬁcient in p53 pathway components p19/ARF
or p21WAF1/Cip1 retain Nutlin-3a sensitivity.
We hypothesised that Nutlin-3a could be applied to the
HIMA as a counter-screen following senescence bypass to
discriminate between immortal HUF clones containing WT
TP53 and those with mutation or loss of TP53. We ﬁrst
examined the effect of Nutlin-3a treatment on cell growth
and p53 pathway activation using primary HUFs and previ-
ously established immortal HUF cell lines with and without
mutated TP53. We then determined whether sensitivity or
resistance to Nutlin-3a treatment of immortal HUF clones,
soon after their emergence from senescent cultures, was
predictive of WT or mutated TP53 upon sequence analysis of
the DNA. We report that Nutlin-3a can indeed speciﬁcally
select for the growth of HUF clones in which TP53 is mutat-
ed and that the majority of mutants can be identiﬁed within
2.5 months of initiating the HIMA.
Material and Methods
HUF cultures
Primary and immortalised Xpa-WT and Xpa-Null HUFs
were derived from embryos of inter-crossed Hupki1/1;Xpa1/2
mice as described previously.25 HUFs were cultured in growth
medium (Dulbecco’s modiﬁed medium (Invitrogen #31966–
021) supplemented with 10% fetal bovine serum (Invitrogen
#26140–079) and 100 U/mL penicillin and streptomycin (Invi-
trogen #15140–130)) at 378C/5% CO2 in either 3% O2 (prima-
ry HUFs) or 20% O2 (immortalised HUFs), adjusted using an
incubator ﬁtted with an oxygen sensor and a nitrogen source.
For passaging cells were detached with 0.05% trypsin-EDTA
(Invitrogen #25300–062), suspended in growth media and
reseeded at the desired dilution or cell number.
HUF immortalisation assay (HIMA)
Xpa-WT and Xpa-Null primary HUFs were immortalised fol-
lowing treatment with 3-nitrobenzanthrone (3-NBA) or 0.1%
DMSO control as described previously.25 Cell lines were named
according to Xpa status (XW: Xpa-WT, XN: Xpa-Null) and
treatment (C: control, 3N: 3-NBA), followed by the clone num-
ber. A panel of immortal clones generated after treatment6 1
mM 3-NBA for 23 48 hr, including nine TP53-mutants and ﬁve
clones retaining WT TP53 (Supporting Information Table 1),
What’s new?
Because half of human tumors carry mutations in the TP53 tumor suppressor gene, a mammalian cell culture system reproduc-
ing the diverse mutations seen in patients is necessary to properly study functional impact. Here the authors report a significant
improvement to an existing model system using fibroblasts from human TP53 knock-in mice (HIMA). They show that treating
cells with Nutlin-3a, an inhibitor of the destabilizing cofactor MDM2, efficiently selects for the growth of TP53-mutated immortal-
ized cells, while selecting against TP53-wild type cells, thus increasing specificity and efficiency of TP53 mutagenesis.
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were used for an initial assessment of HUF responses to Nutlin-
3a. To assess a Nutlin-3a counter-screen in parallel to a HIMA, a
further 36 cultures of Xpa-WT or Xpa-Null primary HUFs were
treated with 1 mM 3-NBA for 1 3 48 hr and passaged until
immortalised clones emerged from the senescent cultures. Each
clone was subjected to a counter-screen with Nutlin-3a as
described below and continually passaged until immortalised cell
lines were established (12 passages).
Treatment with Nutlin-3a
Nutlin-3a (Cayman Chemicals #18585) was dissolved in
DMSO to 10 or 20 mM and stored in aliquots at 2208C. For
cell treatment, Nutlin-3a was diluted in complete growth medi-
um to ﬁnal concentrations up to 10 or 20 mM (0.1% DMSO).
Nutlin-3a counter-screen of HUFs during the HIMA
A Nutlin-3a counter-screen was conducted on clones from the
HIMA described above. As proliferating clones emerged from
senescent cultures (1–3 months after initiating the immortalisa-
tion assay; passage 6–10), each clone was split to two wells of a
six-well plate (note that the time required for senescence bypass
and the subsequent doubling rate was variable between clones).
One well was treated with 10 mMNutlin-3a while the other was
left untreated and maintained according to the assay described
by Kucab et al.25 After 5 days, Nutlin-3a-treated cells were
visually inspected under the microscope to determine whether
the culture was resistant (similar morphology and growth rate
compared to untreated wells), sensitive (all cells observed to
be growth-arrested, possibly enlarged), or exhibited a mixed
response (both sensitive, growth-arrested cells and resistant,
proliferating cells present).
Cultures with a mixed response to Nutlin-3a. After treat-
ment, Nutlin-3a-containing medium was removed from the cells
and replaced with normal growth medium. When the Nutlin-3a-
resistant population reached 60–80% conﬂuency, cultures were
expanded from six-well plates, ﬁrst to 25-cm2 ﬂasks, then to
75-cm2 ﬂasks and then diluted 1:20 at least once before further
analysis. Nutlin-3a-resistant cultures were designated with an
“R” following the name of the parental clone.
Nutlin-3a-sensitive cultures. After treatment, Nutlin-3a-
containing medium was removed from the cells and replaced
with normal growth medium. Cultures were visually inspected
for recovery of proliferation over the next 7 days; those that rap-
idly recovered (3 days) were expanded and diluted as described
above for Nutlin-3a-resistant cultures. Sensitive cultures that
recovered from Nutlin-3a treatment were designated with “rec”
following the name of the parental clone.
Isolation of single cell clones from immortalised
HUF cell lines
Dilutions of immortal cell lines XW-3N-14/-14R and XW-
3N-15/-15R were prepared at 2.5 or 5.0 cells/mL in growth
medium and seeded onto 96-well plates (200 mL/well). The
medium was changed every 3–5 days for up to 2 weeks until
single cell clones (SCCs) were established (50–100 cells per
well). SCCs from 6–10 wells per cell line were passaged to
24-well plates and then expanded progressively into larger
vessels (up to 75-cm2 ﬂask) before further analysis.
Cell growth/survival assay
Survival following treatment with Nutlin-3a was assessed by
crystal violet staining. Cells were seeded at 0.75–1.53 103 cells/
cm2 on 96-well plates and treated the following day with
Nutlin-3a diluted in growth medium up to 10 mM (0.1%
DMSO; ﬁve replicate wells per condition). Following treatment,
cells were rinsed with PBS, stained for 15 min with 0.1% (w/v)
crystal violet (Sigma #C3886) in 10% ethanol, washed with PBS
and air-dried. The dye retained by surviving cells was solubilised
in 100 mL of 50% ethanol per well and A595nm was determined
using a plate reader. Data are presented as the percentage of
A595nm in Nutlin-3a-treated cells relative to that of control cells
and are representative of at least two independent experiments.
Western blotting
Cells were treated with Nutlin-3a at 60–80% conﬂuence for
up to 24 hr, washed with PBS and lysed (62.5 mM Tris [pH
6.8], 1 mM EDTA, 2% SDS, 10% glycerol, 1X HaltTM Prote-
ase Inhibitor Cocktail (#1860932 Thermo Scientiﬁc, UK)). b-
Mercaptoethanol (0.1% v/v) and bromophenol blue (0.01%
w/v) were added to each lysate prior to denaturation at 958C
for 5 min. Equal amounts of protein (10–20 mg) were sepa-
rated by SDS-PAGE on 4–12% Bis-Tris gels (NuPAGE;
#NP0336 Invitrogen) and transferred to nitrocellulose mem-
branes. Membranes were incubated with primary antibody
(anti-p53 (#NCL-p53-CM5 Leica Microsystems; 1:1,000),
anti-p21 (#556431 BD Pharmingen; 1:2,000), anti-Mdm2
(#ab16895 Abcam; 1:400), and anti-Gapdh (#MAB374 Millipore,
1:25,000)) followed by species-speciﬁc horseradish peroxidase-
conjugated secondary antibody (Bio-Rad) and bands were
detected by chemiluminescence.26
TP53 mutation analysis
DNA was extracted from cells using the Gentra Puregene Cell
Kit B (Qiagen, #158745), according to the manufacturer’s
instructions. Mutations in human sequences of TP53 (exons
4–9, and ﬂanking splice sites) from DNA were detected as
described recently.10,25
Results
Nutlin-3a selectively inhibits the growth of primary
and immortal HUFs with WT TP53
It was previously shown that Nutlin-3a treatment (5–10 mM for
up to 1 week) inhibited the growth of primary p53-WT MEFs,
while p53-Null MEFs were resistant.22 We therefore investigat-
ed whether HUFs with WT TP53 would also be sensitive to
Nutlin-3a treatment, and whether HUFs carrying mutated (i.e.
non-functional) TP53 would be resistant, using primary HUFs
and a panel of immortal HUF cell lines with WT or mutated
TP53 generated previously (Fig. 1; Table 1).25
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Following treatment with up to 10 mM Nutlin-3a for 24, 72,
or 120 hr, a dose-dependent decrease in the growth of primary
HUFs was observed, with maximal inhibition (85%) occur-
ring in cells treated for 5 days (Fig. 1c). The growth of Xpa-WT
and Xpa-Null HUFs was inhibited to a similar extent (data not
shown for Xpa-Null cells). Cells treated with 10 mM Nutlin-3a
were signiﬁcantly enlarged and ﬂattened (Fig. 1a). This mor-
phology is similar to that of primary HUFs that undergo senes-
cence after prolonged culture at 20% O2. We then assessed the
growth of four immortal HUF cell lines with WT TP53 (XN-
C-322, XW-C-140, XN-3N-104, XN-3N-107) treated with up
to 10 mM Nutlin-3a for 5 days. As observed for primary HUFs,
Figure 1. Nutlin-3a inhibits the growth of TP53-WT primary and immortalised HUFs, while TP53-mutated cell lines exhibit resistance. Cells were
treated6Nutlin-3a (up to 10 mM) for up to 5 days. Cells treated with 0.1% DMSO only served as control. Photomicrographs (1003) of (a)
primary, (b) immortal TP53-WT (XN-C-322), (e), immortal, Nutlin-3a-resistant TP53-MUT (XW-3N-8) and (f) immortal, partially Nutlin-3a-resistant
TP53-MUT (XW-3N-15) HUFs treated610 lM Nutlin-3a for 5 days. (c, d, g and h) Relative cell number was determined by crystal violet staining
and mean values are shown as % control (0.1% DMSO)6SD of five replicate wells. Data are representative of at least two experiments.
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the growth of immortal HUFs with WT TP53 was strongly
inhibited by Nutlin-3a, ranging from 70–95% inhibition at
10 mM (Fig. 1d). The Nutlin-3a-treated immortal cells with
WT TP53 were enlarged and ﬂattened (Fig. 1b), similar to the
morphology of Nutlin-3a-treated primary HUFs.
Next, we examined the growth of nine immortal HUF cell
lines with MUT TP53 in the presence of Nutlin-3a. Each cell
line was initially treated with 10 mM Nutlin-3a (or 0.1%
DMSO) for 5 days and examined under the microscope.
Growth inhibition was assessed qualitatively (i.e. resistant, sen-
sitive or mixed response; Table 1). Representative examples of
Nutlin-3a-treated TP53-MUT cells are shown in Figures 1e and
1f. With the exception of two lines, XW-3N-14 and XW-3N-
15, TP53-MUT HUFs were completely resistant to the growth-
inhibiting effects of Nutlin-3a and maintained a morphology
similar to that of untreated cells (Table 1 and Fig. 1e). Interest-
ingly, XW-3N-14 and XW-3N-15 exhibited a mixed response
to Nutlin-3a, containing both sensitive and resistant cells; clon-
al regions of proliferating cells were surrounded by enlarged,
arrested cells (Fig. 1f). We assessed further the effect of Nutlin-
3a on the growth of TP53-MUT HUFs quantitatively, ﬁnding a
slight decrease (10–20%) in cell growth at 10 mM for resistant
mutants and a marked inhibition (60–70%) for mixed-response
mutants (Figs. 1g and 1h).
Expression and activation of p53 in HUFs following
treatment with Nutlin-3a
We next assessed the ability of Nutlin-3a to stabilise and activate
p53 in HUFs. Initially, primary HUFs with WT TP53 were
treated with 5 or 10 mM Nutlin-3a for 2–48 hr, and the expres-
sion of p53 and its downstream targets p21 and Mdm2 was
assessed by Western blotting (Fig. 2a). p53 expression was maxi-
mally stabilised after 2-hr treatment with Nutlin-3a, with a simi-
lar level of expression maintained after 8 hr. Thereafter, Nutlin-
3a-induced expression of p53 decreased; by 48 hr p53 expression
had nearly returned to the basal level. p21 and Mdm2 were also
induced after only 2-hr treatment with Nutlin-3a, and their
expression was maintained up to 48 hr. Maximal induction of
p21 was observed at 8–24 hr post-treatment, while Mdm2
expression peaked at 2 hr. Similar results were obtained for
Xpa-WT and Xpa-Null HUFs (data not shown).
The impact of Nutlin-3a on p53 signalling was further
evaluated in immortal HUFs (clone XN-3N-107) with WT
TP53 (Fig. 2b). For the most part Nutlin-3a-induced p53 sta-
bilisation, as well as the expression of p21 and Mdm2, in the
immortal HUFs were similar temporally to those observed in
primary HUFs. However, p53 stabilisation and p21 induction
at later timepoints (24 and 48 hr) appeared to be more
robust in immortal HUFs than in primary HUFs. Similar
responses were found in another immortal HUF cell line
with WT TP53, XN-C-327 (data not shown).
Next, p53 expression and activation was examined in nine
TP53-mutated immortal HUF cell lines treated with and with-
out 10 mM Nutlin-3a for 24 hr (Fig. 2c and Table 1). In most
clones, p53 expression was stabilised even in the absence of
Nutlin-3a, as previously reported for HUFs containing mis-
sense mutations in TP53;13 Nutlin-3a treatment did not induce
a further increase in expression. However, some increase of p53
expression upon Nutlin-3a treatment was observed in clone
XW-3N-14. No p53 expression was detected in clone XN-3N-
110, in agreement with the fact that this clone is mutated at the
splice acceptor site for intron 5. Most TP53-mutated HUFs
were not able to induce p21 or Mdm2 expression following
Nutlin-3a treatment; however p21 was induced in clones
XW-3N-9, XW-3N-14 and XW-3N-15, and Mdm2 was
induced in clones XW-3N-14 and XW-3N-15.
TP53 mutations in HUF cell lines with a mixed
response to Nutlin-3a
To explore further the mixed growth response of cell lines
XW-3N-14 and XW-3N-15 to Nutlin-3a, Nutlin-3a-resistant
cells from the cultures that had been treated with Nutlin-3a
for ﬁve days were expanded. The resistant populations (desig-
nated XW-3N-14R and XW-3N-15R) were expanded for two
to three passages and subsequently compared to the parental
lines for their response to Nutlin-3a. Following 5 days of
retreatment with Nutlin-3a, the parental cell lines again
exhibited partial sensitivity to growth inhibition, whereas
XW-3N-14R and XW-3N-15R were almost completely resis-
tant to retreatment (Fig. 3a). Additionally, while p21 and
Mdm2 expression was induced in the parental cell lines fol-
lowing 24-hr treatment with Nutlin-3a, little to no expression
was detected in the Nutlin-3a-resistant sublines (Fig. 3b).
These data indicate that Nutlin-3a-resistance is dependent on
loss of WT p53 transcriptional activity.
In order to determine whether the Nutlin-3a-resistance of
XW-3N-14R and XW-3N-15R could be explained by addi-
tional or altered TP53 mutation(s) in a subpopulation of the
parental line, single cell clones were generated for XW-3N-
14/-14R and XW-3N-15/-15R. TP53 (exons 4–9) was then
sequenced from each single cell clone (Supporting Informa-
tion Table 2). Note that in the original parental populations,
XW-3N-14 harboured A161P and R249S mutations while
XW-3N-15 carried A161G and L194R mutations.
All single cell clones isolated from XW-3N-14 were
mutated at codon 249 (Supporting Information Table 2).
However, only two of six clones were mutated at codon 161;
the other four clones were wild-type at this site. Interestingly,
all of the single cell clones isolated from the Nutlin-3a-
resistant line XW-3N-14R were mutated at both 249 and
161. This indicates that cells harbouring only the R249S
mutant were sensitive to Nutlin-3a and the additional A161P
mutation was required for resistance to Nutlin-3a. It is
unclear whether the mutations occur on separate TP53 alleles
or whether both mutations are on the same allele with the
second allele remaining WT.
The single cell clones isolated from XW-3N-15 all contained
heterozygous mutations at both codons 161 and 194 (Supporting
Information Table 2). Likewise, mutations were detected at
codons 161 and 194 in single cell clones from the Nutlin-3a-
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resistant line XW-3N-15R. However, the mutations in ﬁve out of
six single cell clones from the Nutlin-3a-resistant line were
homo-/hemizygous. Most likely the two mutations occurred on
the same allele, and the second (WT) allele, retained by the
Nutlin-3a-sensitive cells in the parental line, was lost in the
Nutlin-3a-resistant cells. It is unclear whether Nutlin-3a induced
loss of the WT allele (i.e. LOH) or whether Nutlin-3a-treatment
selected for a small population of the parental cell line that had
already undergone LOH. Regardless, loss of the WT allele
appears to be required for Nutlin-3a resistance in this mutant.
TP53-mutated clones are selectively resistant
to a Nutlin-3a counter-screen during the HIMA
The results of the initial stage of this study indicated that
treatment with Nutlin-3a for 5 days could be used to distin-
guish between immortal HUF clones containing WT or MUT
TP53. We next sought to determine whether a counter-screen
with Nutlin-3a could be integrated as part of the HIMA.
Therefore, a HIMA was conducted according to the standard
protocol with a Nutlin-3a-counter-screen performed in paral-
lel (Fig. 4). Seventy-two cultures of primary HUFs (36 Xpa-
Table 1. The effect of Nutlin-3a on cell growth and p53 activity in TP53-mutant HUF cell lines established A) prior to and B) in parallel to a
Nutlin-3a counter-screen
TP53 mutation status
Response of HUF cell line
to Nutlin-3a
p53 mutant function
(other studies)
HUF cell line ID1 Mutation Zygosity
Growth inhibition
(5 days)
Protein
induction (24 hr)
Activity2 Dominant negativep21 Mdm2
A) Established prior to a Nutlin-3a counter-screen
XW-3N-7 Y236C Homo-/hemi- Resistant – – NF N/A
XW-3N-8 H179N Homo-/hemi- Resistant – – PF Yes3
XW-3N-9 K120M Homo-/hemi- Resistant " – NF N/A
XW-3N-14 A161P
R249S
Hetero-
Hetero-
Mixed " " PF
NF
N/A
Yes3,4
XW-3N-15 A161G
L194R
Hetero-
Hetero-
Mixed " " PF
NF
No4
N/A
XN-3N-105 R273L Hetero- Resistant – – NF Yes3,4
XN-3N-110 intron 5 (SA) Homo-/hemi- Resistant – – N/A N/A
XN-3N-117 V157F Hetero- Resistant – – NF Some3
XN-3N-120 V157F Hetero- Resistant – – NF Some3
B) Established in parallel to a Nutlin-3a counter-screen
XW-3N-29 intron 3 (SA) Homo-/hemi- Resistant – – N/A N/A
XW-3N-37 R282W Homo-/hemi- Resistant – – NF Some3, no4
XW-3N-43 R248W Hetero- Resistant " – NF Yes3
XW-3N-54 H178Q
H179P
Hetero-
Hetero-
Resistant – – NF
PF
N/A
N/A
XW-3N-55 R175L Homo-/hemi- Resistant " " PF No3
XW-3N-59 R158L Homo-/hemi- Resistant – – NF Some3
XN-3N-136 G245R Homo-/hemi- Resistant – – NF Yes3
XN-3N-137 G244A Hetero- Resistant – – NF N/A
R249T Hetero- NF N/A
XN-3N-140 C277F Hetero- Resistant – – NF N/A
XN-3N-141 C277Y Hetero- Sensitive;
rapid recovery
" " NF Yes3, no4
XN-3N-151 c124, frameshift Homo-/hemi- Resistant – – N/A N/A
XN-3N-156 R273S Hetero- Resistant – – NF Yes5
XN-3N-157 intron 8 (SA) Homo-/hemi- Resistant – – N/A N/A
1XW5 Xpa-WT; XN5 Xpa-Null; 3N5 3-NBA-treated.
2The overall transactivation activity of the mutant in a yeast functional assay published by Kato et al.4 (NF5 non-functional, PF5 partially functional,
F5 functional, N/A5 not assessed).
3Dearth et al.27
4Marutani et al.28
5Mitsumoto et al.29
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WT, 36 Xpa-Null) were treated with 3-NBA to induce muta-
tions and then passaged until senescent crisis. As immortal-
ised clones emerged from the cultures and exhibited robust
proliferation (passage 6–10; 1–3 months), each was treated
610 mM Nutlin-3a for 5 days. The sensitivity or resistance of
each clone was assessed by visual inspection under the
microscope. Following treatment, Nutlin-3a-containing media
was replaced with normal media for all sensitive clones, and
treated cultures were observed for growth for an additional 7
days. The response of each clone is listed in Supporting
Information Table 3. The parallel, untreated (2Nutlin-3a)
culture for each clone was continuously passaged until
immortalisation was completed.
Eleven clones (XW-3N-29, 237, 243, 255, 259; XN-3N-
136, 2137, 2140, 2151, 2156, 2157) were completely resis-
tant to Nutlin-3a. One clone (XW-3N-54) exhibited a mixed
response to Nutlin-3a treatment at passage 9 but was complete-
ly resistant when retested at passage 13. Interestingly, one clone
(XN-3N-141) was very sensitive to Nutlin-3a but exhibited
robust recovery 2 to 3 days after Nutlin-3a-containing media
was replaced with normal growth media. The response of
XN-3N-141 did not change when the clone was retested at a
later passage. After 7 days in normal media post-treatment,
varying degrees of recovery were observed for some other Nutlin-
3a-sensitive clones while most clones remained completely growth
arrested.
Figure 2. Induction of p53, p21 and Mdm2 in primary and immortal HUFs treated with Nutlin-3a. Protein expression of p53, p21 and Mdm2
was assessed by Western blotting of whole cell lysates. Gapdh served as a loading control. (a) Primary or (b) immortal HUFs with WT TP53
(clone XN-3N-107) were treated for 2, 8, 24 or 48 hr65 or 10 lM Nutlin-3a. (c) Immortal HUFs with mutated TP53 were treated without
(2) or with (N) 10 lM Nutlin-3a for 24 hr.
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Upon completion of immortalisation (12 passages),
TP53 (exons 4–9) was sequenced from each clone. TP53
mutations were identiﬁed in all 12 clones that were resistant
to Nutlin-3a (Table 1), whereas only one Nutlin-3a-sensitive
clone, XN-3N-141, harboured a TP53 mutation.
Finally, each clone (12 passages) harbouring a TP53
mutation was treated6Nutlin-3a for 24 hr to assess the
expression of p53, p21 and Mdm2 by Western blotting (Table
1 and Fig. 5a). A high level of constitutive p53 expression was
observed for eight of the HUF cell lines carrying missense
mutations, which was not increased by Nutlin-3a treatment.
With the exception of XN-3N-43 (R248W), these clones were
incapable of inducing p21 or Mdm2 expression in response to
Nutlin-3a. XN-3N-43 exhibited constitutive p21 expression,
but was unable to induce Mdm2. Two clones, XW-3N-55
(R175L) and XN-3N-141 (C277Y), expressed a low basal level
Figure 3. HUF cell lines exhibiting a mixed response to Nutlin-3a contain a Nutlin-3a-resistant subpopulation. Growth and p53 activation in
response to treatment with Nutlin-3a was compared in parental (XW-3N-14 and 215) and Nutlin-3a-resistant (XW-3N-14R and 215R) cells.
(a) Relative cell number following 5 days treatment with Nutlin-3a was determined using crystal violet staining and mean values are shown
as % of control6SD of five replicate wells. Data are representative of at least two experiments. (b) Expression of p53, p21 and Mdm2610
lM Nutlin-3a (24 hr) was assessed by Western blotting. Gapdh served as a loading control.
Figure 4. Schematic of the HUF immortalisation assay (HIMA) including a counter-screen with Nutlin-3a. Primary HUFs were treated with 1
mM 3-NBA and serially passaged at 80 to 90% confluence until senescent crisis (P5–P7). As immortalised clones emerged (P7–P9),
each culture was split to two wells and treated 610 mM Nutlin-3a for 5 days. Following treatment, clones were classified as sensitive or
resistant to Nutlin-3a. Untreated cells were continuously cultured until completion of immortalisation (P121) and then DNA sequenced to
identify TP53 mutations. “P” refers to passage number.
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of p53 that increased following Nutlin-3a treatment and were
the only mutants capable of inducing both p21 and Mdm2 in
response to Nutlin-3a. Finally, the three clones harbouring
mutations at intronic splice sites exhibited no p53 expression
and weak-to-no induction of p21 or Mdm2.
Reversible Nutlin-3a sensitivity of a TP53-mutated
clone (XN-3N-141)
As described above, clone XN-3N-141 (C277Y) was sensitive to
Nutlin-3a, despite harbouring a TP53mutation. Five days of treat-
ment with Nutlin-3a caused the cells to arrest, but they remained
morphologically normal and were not enlarged (Fig. 5b), in con-
trast to the morphological changes observed in Nutlin-3a-sensitive
TP53-WT clones (compare with Fig. 1b). However, once Nutlin-
3a was removed and replaced with normal media, XN-3N-141 cell
growth recovered within 2 to 3 days (Fig. 5b). This rapid recovery
was not observed in any of the clones containing WT-TP53. The
cells that recovered from Nutlin-3a-treatment (XN-3N-141rec)
were expanded and retested. Both the parental line, XN-3N-
141rec, and the Nutlin-3a-selected line, XN-3N-141R, arrested
when treated with Nutlin-3a for 5 days (Fig. 5c) and both exhib-
ited p21 and Mdm2 induction after Nutlin-3a treatment for 24 hr
(Fig. 5d).
Discussion
The HIMA is a unique tool in the current arsenal of mutagen-
esis assays, enabling the generation and selection of mutations
in a human cancer-related gene (i.e. TP53) within mammalian
Figure 5. Evaluation of the response to Nutlin-3a in TP53-mutant HUF cell lines established in parallel to a Nutlin-3a counter-screen. (a) Protein
expression of p53, p21 and Mdm2 was assessed by Western blotting whole cell lysates of HUFs treated without (2) or with (N) 10 lM Nutlin-3a
for 24 hr. Gapdh served as a loading control. (b–d) Growth and p53 activation in response to treatment with Nutlin-3a was compared in the
Nutlin-3a-sensitive TP53-mutant clone XN-3N-141 and subline XN-3N-141rec (generated following an initial 5-day treatment with Nutlin-3a). (b)
Photomicrographs (1003) of untreated (0.1% DMSO) cells, cells treated with 10 lM Nutlin-3a for 5 days (1Nut-3a) and cells allowed to recover
for 2 days following Nutlin-3a treatment (recovery). (c) relative cell number following 5 days treatment with Nutlin-3a was determined using crys-
tal violet staining and mean values are shown as % of control6SD of five replicate wells. Data are representative of at least two experiments.
(d) Expression of p53, p21 and Mdm2610 lM Nutlin-3a (24 hr) was assessed by Western blotting. Gapdh served as a loading control.
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cells. Mutation or loss of TP53 is a key mechanism in the
immortalisation of HUFs. However, because other genetic
alterations also enable immortalisation of HUFs, the HIMA is
not selective only for TP53-mutated cells. In an attempt to
improve the selectivity of the HIMA, we examined whether
the Mdm2-inhibitor Nutlin-3a could be used to identify clones
harbouring TP53 mutations. In this study, over 86 immortal
HUF clones were tested with Nutlin-3a, including 22 with
identiﬁed TP53 mutations. We showed that Nutlin-3a stabi-
lised and activated WT p53, leading to growth suppression of
all primary and immortal HUF cell lines with WT TP53. On
the other hand, immortal HUFs harbouring TP53 mutations
were, for the most part, resistant to Nutlin-3a-induced growth
inhibition and p53 activation. Only 1/22 clones (XN-3N-141)
with mutated TP53 was sensitive to Nutlin-3a; however, this
clone recovered rapidly upon removal of Nutlin-3a in a man-
ner that was not observed for any of the TP53-WT clones.
Importantly, we found that when immortal HUF clones were
treated with Nutlin-3a soon after their emergence from senes-
cent cultures during an immortalisation assay, resistance to
Nutlin-3a was highly predictive of the presence of TP53 muta-
tion(s). Therefore, we propose that future HIMAs may include
a Nutlin-3a counter-screen, whereby only Nutlin-3a-resistant
clones are assessed for TP53 mutations and Nutlin-3a-sensitive
clones are discarded.
Although most TP53-mutated clones were completely
resistant to Nutlin-3a-induced growth suppression, two
clones exhibited a mixed response to Nutlin-3a treatment
(i.e. contained both sensitive and resistant cells). In these
cases cells retaining one WT TP53 allele, in addition to the
mutated allele, remained Nutlin-3a-sensitive, whereas cells
that acquired a second mutation or lost the WT TP53 allele
were Nutlin-3a-resistant. As most heterozygously-mutated
clones were completely resistant to Nutlin-3a, the Nutlin-3a-
sensitivity of some cells harbouring both mutant and WT
p53 may be explained by a mutant that retains some WT
functionality or by a non-functional mutant that fails to act
dominant-negatively against the WT protein. Indeed, while
p21 and Mdm2 expression were efﬁciently induced by
Nutlin-3a in clones XW-3N-14 and XW-3N-15 (which were
Nutlin-3a-sensitive and retained a WT TP53 allele), the
Nutlin-3a-resistant sublines XW-3N-14R (which acquired a
second mutation) and XW-3N-15R (which lost the WT TP53
allele) were unable to induce expression of the p53 targets
p21 and Mdm2 following Nutlin-3a treatment. Although the
TP53 mutations in the Nutlin-3a-sensitive clones clearly per-
mitted these cells to escape from senescence and to immor-
talise, perhaps the level of WT p53 stabilisation induced by
Nutlin-3a overwhelmed the mutant p53 protein to an extent
not observed under normal growth conditions.
Interestingly, the one clone (XN-3N-141) that exhibited
reversible sensitivity to Nutlin-3a harboured a mutation at
the same TP53 codon (277) mutated in another clone that
was completely resistant to Nutlin-3a (XN-3N-140); in both
cases the mutation was heterozygous. In XN-3N-141 the
mutation converts C277 to Y277, while in XN-3N-140 C277
is converted to F277. The ability to induce p21 and Mdm2
expression was lost in the C277F mutant, but retained in the
C277Y mutant. This suggests that the speciﬁc amino acid
change generated by a mutation plays an important part
both in the response of a clone to Nutlin-3a and the ability
of the mutant protein to exert dominant-negative effects over
wild-type p53. Further studies to examine additional HUF
cell lines could be performed to determine how frequently, or
rarely, TP53-mutated clones exhibit sensitivity to Nutlin-3a.
The HUF clones generated in previous HIMAs represent
over 100 unique mutations in TP53, including several differ-
ent mutations at the same codon. The functional impact of
these mutations is diverse (i.e. silent, functional, partially-
functional and non-functional) and could be investigated by
screening these clones for their response to Nutlin-3a.
Notably, the majority of TP53-mutated clones were identi-
ﬁed as resistant to Nutlin-3a within 2.5 months of initiating
the HIMA (Supporting Information Table 3). Thus, a Nutlin-
3a counter-screen could be used to identify mutants within a
cut-off of 2.5 months. Limiting the detection of mutant (Nut-
lin-3a-resistant) clones to a 2.5 month period and discarding
WT (Nutlin-3a-sensitive) cultures would greatly reduce the
labour of the assay. The current study suggests that few
mutants would be missed by this approach.
One potential limitation of the Nutlin-3a counter-screen
would be the likely Nutlin-3a-sensitivity of clones carrying
silent TP53 mutations, since these clones would retain WT
p53 functional activity. However, silent mutations have been
observed infrequently in previous HIMAs and were not
found in the current study.5 It is also unclear whether other
genetic alterations, particularly those affecting p53 pathway
components, would impact the response of an immortal
clone to Nutlin-3a. Previous studies indicated that MEFs
lacking p19 and p21 are still sensitive to Nutlin-3a, although
loss of p21 appears to hinder the ability of Nutlin-3a to
induce permanent cell cycle arrest.22 Another study showed
that loss of p19 potentiated Nutlin-3a-induced growth inhibi-
tion of neuroblastoma cells.30 Further, MDM2 overexpression
reportedly enhances cell sensitivity to Nutlin-3a.31 We predict
that the unique nature of each TP53 mutant (e.g. transactiva-
tional capability or dominant negative effects), in combina-
tion with the presence or loss of the WT TP53 allele, will be
the main determinant of Nutlin-3a-resistance or sensitivity.
Although Nutlin-3a is considered to be a non-genotoxic
activator of p53, two studies have shown that long-term
exposure to Nutlin-3a can induce TP53 mutations. In the
ﬁrst report, SJSA-1 osteosarcoma cells were exposed to four
cycles of treatment with 10 mM Nutlin-3a for 72 hr followed
by a recovery period.32 Five unique TP53 mutations not
found in the parental cell line were identiﬁed in subclones. In
a separate study, six different cancer cell lines were exposed
continuously to Nutlin-3a for up to 14 passages.33 Here,
28 out of 35 Nutlin-3a-adapted sublines contained TP53
mutations. This includes 8 mutants that were generated from
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a single cell clone of the TP53-WT cell line UKF-NB-3, indicat-
ing that Nutlin-3a did not merely select for rare mutants
already present in the cell line. These data suggest that sponta-
neous TP53 mutations may be selected for under the stress of
Nutlin-3a treatment. The authors postulated that perhaps deﬁ-
ciencies in DNA repair or replication ﬁdelity in cancer cells can
enhance the induction of spontaneous mutations. The potential
for Nutlin-3a to induce TP53 mutations would not be an issue
when it is used to counter-screen immortal HUFs in the man-
ner proposed here. Resistance or sensitivity to short-term (5
days) Nutlin-3a treatment simply serves to identify TP53-WT
and TP53-MUT immortal clones. TP53 should then be
sequenced from cultures that were not exposed to Nutlin-3a,
although it may also be useful to sequence TP53 from Nutlin-
3a-resistant cells expanded following Nutlin-3a treatment in
some cases, as done in this study.
In conclusion, this proof-of-concept study has shown that
resistance to the Mdm2-inhibitor Nutlin-3a is a common
feature of immortal HUFs harbouring mutated TP53; thus, a
Nutlin-3a counter-screen during the HIMA can be used to
select for TP53-mutated cells and select against TP53-WT
cells soon after the immortal clones become established. In
this way, Nutlin-3a-sensitive clones can be discarded and
TP53 mutations assessed only in Nutlin-3a-resistant clones,
improving the efﬁciency of the assay. More assays can be
performed, more clones screened, and more TP53 mutations
generated, thereby enhancing the study of mutagenesis of a
gene with so many possible inactivating mutations.
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